Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-702 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| VX-702 | DRUG | - |
Inclusion Criteria: * Adult patients 18 to 75 years of age with active RA * Must have been taking MTX for at least 6 months * No concurrent DMARD treatment (other than a stable dose of MTX) Exclusion Criteria: * Planned major surgery (e.g., joint replacement) within the duration of the treatment ...
Top 20 of 31 competitors
VX-702 is an investigational oral small molecule that was studied for the treatment of rheumatoid arthritis. It was developed by Vertex Pharmaceuticals and reached Phase 2 clinical testing in that indication. It is not an approved therapy and is no longer listed as an active development program.
VX-702 targets MAPK14, also known as p38 MAP kinase. It acts as an inhibitor of this enzyme. The compound is described in trial titles as an investigational oral p38 MAP kinase inhibitor, and its mechanism relates to blocking this signaling pathway.
VX-702 was developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. The company sponsored the Phase 2 rheumatoid arthritis studies of the compound.
VX-702 reached Phase 2 clinical development. Both of its rheumatoid arthritis trials are completed, and no trials are currently active. It is an investigational agent and is not an approved medicine.
VX-702 was evaluated in two completed Phase 2 trials in rheumatoid arthritis: NCT00395577, which enrolled 120 patients, and NCT00205478, which enrolled 300 patients. Both were randomized, double-blind studies conducted across sites in Eastern and Central Europe.